Logo image of BDSX

BIODESIX INC (BDSX) Stock Overview

NASDAQ:BDSX - US09075X1081 - Common Stock

0.47 USD
+0 (+1.08%)
Last: 8/27/2025, 8:00:01 PM
0.47 USD
0 (0%)
Pre-Market: 8/28/2025, 5:38:32 AM

BDSX Key Statistics, Chart & Performance

Key Statistics
52 Week High2
52 Week Low0.17
Market Cap68.92M
Shares146.63M
Float67.86M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.29
PEN/A
Fwd PEN/A
Earnings (Next)10-30 2025-10-30/amc
IPO10-28 2020-10-28
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Providers & Services
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Services


BDSX short term performance overview.The bars show the price performance of BDSX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40 -40

BDSX long term performance overview.The bars show the price performance of BDSX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of BDSX is 0.47 USD. In the past month the price increased by 24.17%. In the past year, price decreased by -76.02%.

BIODESIX INC / BDSX Daily stock chart

BDSX Competitors/Peers

The largest stocks on the US markets in the "Health Care Services" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
CVS CVS HEALTH CORP 11.35 91.23B
CI THE CIGNA GROUP 10.68 80.07B
LH LABCORP HOLDINGS INC 18.45 23.21B
DGX QUEST DIAGNOSTICS INC 19 20.10B
FMS FRESENIUS MEDICAL CARE-ADR 12.45 14.76B
BTSGU BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 111.59 14.63B
HIMS HIMS & HERS HEALTH INC 55.01 9.95B
DVA DAVITA INC 14.2 9.84B
GH GUARDANT HEALTH INC N/A 7.92B
CHE CHEMED CORP 20.35 6.63B
RDNT RADNET INC 198.03 5.48B
OPCH OPTION CARE HEALTH INC 21.18 4.64B

About BDSX

Company Profile

BDSX logo image Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Louisville, Colorado and currently employs 273 full-time employees. The company went IPO on 2020-10-28. The firm develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.

Company Info

BIODESIX INC

919 West Dillon Road

Louisville COLORADO US

Employees: 273

BDSX Company Website

BDSX Investor Relations

Phone: 13034170500

BIODESIX INC / BDSX FAQ

What is the stock price of BIODESIX INC today?

The current stock price of BDSX is 0.47 USD. The price increased by 1.08% in the last trading session.


What is the ticker symbol for BIODESIX INC stock?

The exchange symbol of BIODESIX INC is BDSX and it is listed on the Nasdaq exchange.


On which exchange is BDSX stock listed?

BDSX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for BIODESIX INC stock?

12 analysts have analysed BDSX and the average price target is 1.79 USD. This implies a price increase of 279.79% is expected in the next year compared to the current price of 0.47. Check the BIODESIX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BIODESIX INC worth?

BIODESIX INC (BDSX) has a market capitalization of 68.92M USD. This makes BDSX a Micro Cap stock.


How many employees does BIODESIX INC have?

BIODESIX INC (BDSX) currently has 273 employees.


What are the support and resistance levels for BIODESIX INC (BDSX) stock?

BIODESIX INC (BDSX) has a support level at 0.43 and a resistance level at 0.49. Check the full technical report for a detailed analysis of BDSX support and resistance levels.


Is BIODESIX INC (BDSX) expected to grow?

The Revenue of BIODESIX INC (BDSX) is expected to grow by 17.45% in the next year. Check the estimates tab for more information on the BDSX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy BIODESIX INC (BDSX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BIODESIX INC (BDSX) stock pay dividends?

BDSX does not pay a dividend.


When does BIODESIX INC (BDSX) report earnings?

BIODESIX INC (BDSX) will report earnings on 2025-10-30, after the market close.


What is the Price/Earnings (PE) ratio of BIODESIX INC (BDSX)?

BIODESIX INC (BDSX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.29).


What is the Short Interest ratio of BIODESIX INC (BDSX) stock?

The outstanding short interest for BIODESIX INC (BDSX) is 6.07% of its float. Check the ownership tab for more information on the BDSX short interest.


BDSX Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to BDSX. When comparing the yearly performance of all stocks, BDSX is a bad performer in the overall market: 84.02% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BDSX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to BDSX. BDSX has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BDSX Financial Highlights

Over the last trailing twelve months BDSX reported a non-GAAP Earnings per Share(EPS) of -0.29. The EPS increased by 36.96% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -46.82%
ROE -3609.67%
Debt/Equity 41.11
Chartmill High Growth Momentum
EPS Q2Q%0%
Sales Q2Q%11.68%
EPS 1Y (TTM)36.96%
Revenue 1Y (TTM)25.71%

BDSX Forecast & Estimates

12 analysts have analysed BDSX and the average price target is 1.79 USD. This implies a price increase of 279.79% is expected in the next year compared to the current price of 0.47.

For the next year, analysts expect an EPS growth of 17.67% and a revenue growth 17.45% for BDSX


Analysts
Analysts80
Price Target1.79 (280.85%)
EPS Next Y17.67%
Revenue Next Year17.45%

BDSX Ownership

Ownership
Inst Owners33.44%
Ins Owners25.97%
Short Float %6.07%
Short Ratio2.7